Learn More
Of 47 depressed patients, 19 reported the symptom of unpleasant taste. This symptom appeared unrelated to previous drug treatment. Also, in this study, there was no significant association with prognosis, severity or type of depression, or with various historical factors. Despite this, it would seem to be an underreported symptom, worthy of further(More)
Methylene blue, 15 mg/day, was compared with placebo in treatment of severe depressive illness. The 3-week trial was designed to avoid bias by placebo response and also to avoid observer bias. Improvement in patients receiving methylene blue was significantly greater than in those receiving placebo. Methylene blue at a dose of 15 mg/day appears to be a(More)
Lymphoblastoid cell lines established from patients suffering from bipolar manic-depressive psychosis or from a control group have been used to study the metabolism of the polyphosphoinositides in these cells. Cells were incubated for up to 6 h in [3H]inositol and the extent of inositol incorporation into the mono-, di- and triphosphoinositides was measured(More)
Aluminum concentration was measured in serum, whole blood, hair, and urine by neutron activation analysis. Seventy-six nondemented subjects were investigated. Not all assays were done on all subjects (e.g., serum aluminum on 76 subjects, whole blood aluminum on 42 subjects), but tissue aluminum concentrations were estimated on more than one occasion on 32(More)
In two randomized double-blind controlled trials on 63 depressed female in-patients subject to recurrent affective disorder (bipolar and unipolar manic-depressive psychosis) lithium was shown to have major acute antidepressant effects. At the end of three weeks lithium produced more uniform improvement than did imipramine; lithium in combination with(More)
A double-blind cross-over trial of depot flupenthixol in recurrent manic depressive psychosis was carried out. All patients continued on lithium. Eleven patients completed the two-year trial. Flupenthixol appeared to have no prophylactic effect.
A 2-year prophylactic trial was carried out in 31 bipolar manic-depressive subjects, comparing 300 mg/day methylene blue on a double-blind crossover basis with 15 mg/day. All patients were also maintained on lithium. Seventeen patients completed the 2-year trial. During the year the patients were treated with methylene blue at 300 mg/day, they were(More)
Lithium was given to eight aggressive, non-manic-depressive female defectives in a doubleblind placebo-controlled study. The group as a whole showed a reduction in aggression scores while on lithium (p greater than 0.01): three patients became less aggressive,one became worse and two were unchanged. Both affective and predatory aggression seemed to be(More)